

Press Release

Changes of Representative Director and Directors

TOKYO, April 25, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company”) today announced that at a meeting of its Board of Directors held today, it decided changes of Representative Director and Directors as stated below. These changes are subject to approval at the 14th Term Annual Shareholders Meeting and decision at the Board of Directors meeting, both scheduled on June 18, 2019.

1. New Representative Director Candidate

Naoki Okamura

(New) Representative Director, Executive Vice President

(Current) Corporate Executive Vice President, Chief Strategy Officer (CStO)

- Effective date of change: June 18, 2019
- Reason for change: This change is decided in order to pursue Astellas’ growth strategies more vigorously by new leader.

- **Curriculum Vitae of new Representative Director candidate**

Name: Naoki Okamura

Date of Birth: September 18, 1962

Place of Birth: Shizuoka Prefecture

- Resume

March 1985 University of Tokyo, Faculty of Pharmacy

April 1986 Joined Yamanouchi Pharmaceutical Co., Ltd.

October 2010 President & CEO, OSI Pharmaceuticals, Inc.

April 2012 Senior Vice President, Chief Strategy Officer, Astellas Pharma Europe Ltd.

July 2014 Vice President, Licensing & Alliances, the Company

April 2016 Vice President, Corporate Planning, the Company

June 2016 Corporate Executive, Vice President, Corporate Planning, the Company

April 2018 Corporate Executive, Chief Strategy Officer (CStO), the Company

April 2019 Corporate Executive Vice President, Chief Strategy Officer (CStO), the Company (present post)

Ownership of shares: 0 shares (as of March 31, 2019)

2. Candidates for Directors (excluding Directors who are Audit & Supervisory Committee Members)

Name		Current Position
Yoshihiko Hatanaka	Reelection	Representative Director, Chairman of the Board
Kenji Yasukawa	Reelection	Representative Director, President and CEO
Naoki Okamura	New Candidate	Corporate Executive Vice President, Chief Strategy Officer (CStO)
Mamoru Sekiyama	Outside Reelection	—
Keiko Yamagami	Outside Reelection	Lawyer honorary member, Tokyo Seiwa Law Office
Hiroshi Kawabe	Outside New Candidate	Professor Emeritus, Keio University President, Foundation for Promotion of Medical Training
Tatsuro Ishizuka	Outside New Candidate	Director, Hitachi Construction Machinery Co., Ltd. Advisor, Hitachi, Ltd.

The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act.

3. Candidate for Director who is an Audit & Supervisory Committee Member

Name		Current Position
Haruko Shibumura	Outside New Candidate	Partner Lawyer, Homma & Partners Outside Audit & Supervisory Board Member, NICHIREKI CO., LTD. Outside Director, TAMURA Corporation

The current position describes significant concurrent positions at other organizations pursuant to the Companies Act. Ms. Haruko Shibumura was elected as a substitute Director who is an Audit & Supervisory Committee Member at the 13th Term Annual Shareholders Meeting on June 15, 2018, but will resign from the substitute Director who is an Audit & Supervisory Committee Member at the start of the 14th Term Annual Shareholders Meeting.

4. Candidate for substitute Director who is an Audit & Supervisory Committee Member

Name		Current Position
Raita Takahashi	Outside	Representative, TAKAHASHI Accounting & Tax office Outside Audit & Supervisory Board Member, Alpha Group Inc. Representative Director, Yoshida Management Co. Ltd.

The current position describes significant concurrent positions at other organizations pursuant to the Companies Act.

5. Directors to be retired

Outside Director Yoshiharu Aizawa

Outside Director, Audit & Supervisory Committee Member Hitoshi Kanamori

6. The Board of Directors as from June 18, 2019 (planned)

Yoshihiko Hatanaka (Representative Director, Chairman of the Board)

Kenji Yasukawa (Representative Director, President and CEO)

Naoki Okamura (Representative Director, Executive Vice President)

Mamoru Sekiyama (Outside Director)

Keiko Yamagami (Outside Director)

Hiroshi Kawabe (Outside Director)

Tatsuro Ishizuka (Outside Director)

Tomokazu Fujisawa (Director, Audit & Supervisory Committee Member)

Hiroko Sakai (Director, Audit & Supervisory Committee Member)

Noriyuki Uematsu (Outside Director, Audit & Supervisory Committee Member)

Hiroo Sasaki (Outside Director, Audit & Supervisory Committee Member)

Haruko Shibusawa (Outside Director, Audit & Supervisory Committee Member)

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473